Barclays
http://www.barclays.com/Barclays plc is a global financial services provider engaged in retail and commercial banking, credit cards, investment banking, wealth management and investment management services. It has an extensive international presence in Europe, the United States, Africa and Asia. In addition, the bank is one of the ten largest banks in the world measured by market capitalization. Barclays is headquartered in London, England.
-
Notable Analyst Rating Changes 05/22: (BMY) (CREE) (TEX) Upgraded; (IGTE) (CCL) (NCT) Downgraded
-
Barclays on U.S. Biopharmaceuticals: Fate of Nucs Under Harsh Scrutiny - More Angst for IDIX; GILD Widens Lead
-
Notable Analyst Rating Changes 08/24: (USG) (TCB) (BMY) Upgraded; (ADSK) (GGP) (BIG) Downgraded
-
Barclays Lowers Outlook on Idenix Pharmaceuticals (IDIX); Clarity on FDA Clinical Hold (BMY, VRTX, GILD)
-
Gilead Sciences (GILD) Surges As Bristol-Myers' (BMY) Hep C Drug Has Major Setback
-
Barclays Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
-
Top 10 News Items 7/2-7/6: Private Sector Showed Slowest Pace of Job Growth in 10 Months; Central Banks React; Mergers Get Serious on Monday
-
Barclays on AstraZeneca (AZN): Acquisition of AMLN Makes Strategic Sense but High Price Tag
-
Barclays Remains Bullish on Vertex (VRTX); Upside to Phase I Data
-
Barclays on Healthcare: Top Takeaways from our Second Annual Therapeutics Symposium
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
Barclays Mintains an 'Overweight' on Bristol-Myers (BMY); Steady Pipeline Execution in Q3: November an Icremental Mnth for Eliquis
-
Notable Analyst Rating Changes 10/28: (AMD) (LLY) (GS) Upgraded; (MDR) (BMY) (ED) Downgraded
-
Barclays on U.S. Major Pharmaceuticals: Q3 Preview: BMY and PFE to Stand Apart From the Defensive Play Story
-
Pre-Open Movers 9/19: (GR) (TYC) (LEN) Higher; (JKS) (AMAT) (RAH) Lower (more...)
-
UPDATE - Barclays Downgraded Pfizer (PFE) to Equalweight; Inferior Revenue Recovery Post 'Patent Cliff' Through 2020
-
Barclays Maintains an 'Equalweight' on Eli Lilly (LLY); No Signs of Fatigue at the Edge of the Cliff; Pipeline Risk Unabated
-
Barclays on U.S. Diagnostics: FDA Issues draft guidance on companion diagnostics; Positive read for QGEN
-
Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); ARISTOTLE Delivers One-Two Punch; Eliquis Poised to be the Market Leader
-
Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); Nulojix Marks Second Hit in a Row; ARISTOTLE Top Line Remains The Focus
-
Barclays on U.S. Major Pharmaceuticals: Pipelines Revived? Making Strides in Oncology, Cardiology, and Virology
-
Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
-
Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Management Dinner Feedback: Myriad Options, but How to Go Foward in HCV?
-
Barclays on U.S. Major Pharmaceuticals: 1Q11 Preview: Restructuring or New Products - Which Is The Lifeline For Pharma?
-
Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); Leading in the Evolving HCV Landscape
-
Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); Ipilimumab: Two Birds with One Stone
-
Barclays on U.S. Major Pharmaceuticals: U.S. Major Pharma 2011 Outlook: A View Beyond the Cliff
-
Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); APPRAISE-2 Discontinuation Has Limited Implications for ARISTOTLE
-
U.S. Major Pharmaceuticals: Q3 Preview: A hit but not a home run
-
Daily State of the Markets 10/04: Pressing Pause (Again)
-
Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Expect Outperformance With Core Franchise Stability
-
Notable Analyst Rating Changes 03/05: DISH, TIVO, CWTR, CIEN, BMY Upgraded; WEN, TSN, AUY, WBD Downgraded
-
Notable Analyst Rating Changes: MS, BA, UNH, INTC, UPL, FTO, More Upgraded; BMY, CHK, BSX, MELI, More Downgraded
-
Notable Analyst Rating Changes 12/22: ATHX, IAG, BUCY, AMTD Upgraded; XTO, IMAX, WRC Downgraded
-
Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Raises PT
-
Notable Analyst Rating Changes 7/15: GS, ALU, ICE, MCO, ADBE, MI Upgraded; PTR, PAR, UFS, PCL Downgraded
-
David Moenning's Daily State of the Markets: 4/29
-
Notable Analyst Rating Changes 4/29: ATVI, OZM, AMX, DNDN Upgraded; BMY, WFMI, M, SFD Downgraded
-
Notable Analyst Rating Changes 4/3: RIMM, DVN, ICE, ELN Upgraded; DIS, BMY, MON, AKAM Downgraded
-
David Moenning's Daily State of the Markets: 1/27
-
David Moenning's Daily State of the Markets: 10/23
